Literature DB >> 29445431

Outcome, Recurrence and Mortality after Non-Valvular Atrial Fibrillation Stroke: Long-Term Follow-Up Study.

Antonio Arauz1, Francisco Ruiz-Navarro1, Miguel A Barboza1, Angelica Ruiz1, Jonathan Colin1, Marisela Reyes1, Humberto Silos1, Carlos Cantu-Brito1, Luis Murillo-Bonilla1, Fernando Barinagarrementeria1.   

Abstract

OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is a major risk factor for ischemic stroke (IS) and a powerful predictor of mortality. This study investigates early and long-term outcome among patients with IS secondary to NVAF and identify the main factors associated with poor outcome, recurrence, and death.
METHODS: We analyzed the data from our consecutive NVAF acute IS database, over a period of 23 years. The endpoints were bad outcome (Modified Rankin Score ≥3), recurrence, and mortality at discharge, after 6 months, 12 months, and final follow-up. Multivariate Cox and Kaplan-Meier analysis were used to estimate the probability of death.
RESULTS: 129 consecutive acute IS patients were included (77 [59.7%] females, mean age 70.2 ± 10.1 years). Discharge, 6 and 12 months bad outcome was 62%, 63%, and 61%, respectively. After a median follow-up of 17 months (IQR 6-54.5), 35.6% patients had bad outcome, 21.7% had recurrence and 36.4% died. The recurrence and death annual rates were 19.1% and 6.32%. The absence of oral anticoagulation (OAC) and NIHSS score > 12 were the strongest predictors of mortality.
CONCLUSIONS: IS secondary to NVAF has a high rate of stroke recurrence and mortality in our population, with the absence of OAC and major stroke as the main risk factors.

Entities:  

Keywords:  cardioembolic stroke; ischemic stroke; non-valvular atrial fibrillation; oral anticoagulation; prognosis; stroke outcome

Year:  2017        PMID: 29445431      PMCID: PMC5805901     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  21 in total

1.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

Review 2.  Atrial fibrillation.

Authors:  S M Narayan; M E Cain; J M Smith
Journal:  Lancet       Date:  1997-09-27       Impact factor: 79.321

3.  Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project).

Authors:  M Lamassa; A Di Carlo; G Pracucci; A M Basile; G Trefoloni; P Vanni; S Spolveri; M C Baruffi; G Landini; A Ghetti; C D Wolfe; D Inzitari
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

4.  Classification and natural history of clinically identifiable subtypes of cerebral infarction.

Authors:  J Bamford; P Sandercock; M Dennis; J Burn; C Warlow
Journal:  Lancet       Date:  1991-06-22       Impact factor: 79.321

Review 5.  ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation.

Authors:  G Y Lip; D G Beevers
Journal:  BMJ       Date:  1995-11-18

6.  Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation.

Authors:  Emer R McGrath; Moira K Kapral; Jiming Fang; John W Eikelboom; Aengus ó Conghaile; Aengus O Conghaile; Michelle Canavan; Martin J O'Donnell
Journal:  Stroke       Date:  2014-11-06       Impact factor: 7.914

7.  Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial.

Authors:  R Saxena; S Lewis; E Berge; P A Sandercock; P J Koudstaal
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

Review 8.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Alan S Go; Jonathan L Halperin; Warren J Manning
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Long-term survival after ischemic stroke in patients with atrial fibrillation.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  Neurology       Date:  2014-02-14       Impact factor: 9.910

View more
  4 in total

1.  Functional Outcome and Safety of Intracranial Thrombectomy After Emergent Extracranial Stenting in Acute Ischemic Stroke Due to Tandem Occlusions.

Authors:  Philipp Bücke; Marta Aguilar Pérez; Muhammad AlMatter; Victoria Hellstern; Hansjörg Bäzner; Hans Henkes
Journal:  Front Neurol       Date:  2018-11-20       Impact factor: 4.003

2.  The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation.

Authors:  Jiayu Wang; Jia Zhang; Yuan Shen; Xiaowei Xu
Journal:  BMC Cardiovasc Disord       Date:  2019-04-02       Impact factor: 2.298

3.  Analysis of Risk Factors for Poor Short-Term Outcomes in Acute Cardioembolic Stroke Patients without Reperfusion Therapy.

Authors:  Yikun Guo; Min Zhang; Yan Su; Jianfang Liu; Hongran Fu; Qian Wang; Yun Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2021-11-23       Impact factor: 2.570

4.  Is Anticoagulation Necessary for Severely Disabled Cardioembolic Stroke Survivors?

Authors:  Kristaps Jurjans; Baiba Vikmane; Janis Vetra; Evija Miglane; Oskars Kalejs; Zanda Priede; Andrejs Millers
Journal:  Medicina (Kaunas)       Date:  2019-09-13       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.